Organization

Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan

14 abstracts

Abstract

Prospective observational study of nutritional and immunological indices as predictive biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer (ICI-PREDICT study).

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan, Department of Respiratory Medicine, NHO Nagoya Medical Center, Nagoya, Japan, Department of Respiratory Internal Medicine, NHO Higashihiroshima Medical Center, Higashihiroshima, Japan,

Abstract

Pooled analysis on characteristics of nausea and vomiting in patients receiving trastuzumab deruxtecan (T-DXd) in clinical studies.

Org: Samsung Medical Centre, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Memorial Sloan Kettering Cancer Center,

Abstract

A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.

Org: Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Clinical Trial Center and Department of Epidemiology - IRCCS Ospedale Policlinico San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy, Lung Cancer Department, The First Affiliated Hospital of Xiamen University,

Abstract

The impact of PD-L1 expression and co-mutations on outcome of KRAS-driven non-small-cell lung cancer.

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Thoraxklinik, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), University Hospital Heidelberg,

Abstract

Large-scale comparative analysis of clinico-genomic characteristics, treatment outcomes and resistant mechanisms of ALK/ROS1/RET-rearranged non-small cell lung cancer (NSCLC) in a nationwide genomic screening project (LC-SCRUM-Asia/TRY).

Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Sendai Kousei Hospital,

Abstract

Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, GenEros Biopharma Ltd, Institute of Human Diseases and Immunotherapy,

Abstract

A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).

Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Osaka International Cancer Institute, Osaka, Japan, Kanagawa Cancer Center, Itami City Hospital,

Abstract

Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm, phase Ⅱ study.

Org: Affiliated Hangzhou Cancer Hospital, Zhejiang University School of Medicine First Affiliated Hospital, Hangzhou, China, Hangzhou, Zhejiang, China, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Affiliated Hangzhou First People’s Hospital,

Abstract

Immunotherapy with or without radiotherapy in late-line treatment for metastatic esophageal cancer: A real-world study.

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, West China Hospital, Sichuan University, Chengdu Origen Biotechnology,

Abstract

Differential therapeutic benefit of platinum-doublet chemotherapies with ICIs based on the classification by combined with smoking status and PD-L1 expression in patients with advanced NSCLC.

Org: National Cancer Center Hospital East, Kashiwa, Japan, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,

Abstract

Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).

Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,

Abstract

Establishment of a nomogram predictive model for survival and prognosis of 97 patients with different subtypes of lung adenocarcinoma after radical resection.

Org: Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, the Third Affiliated Hospital of Xinjiang Medical University, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China,

Abstract

Cerebrospinal fluid circulating tumor DNA for the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer.

Org: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital,

Abstract

Effect of intrathecal pemetrexed on survival in patients with lung adenocarcinoma with leptomeningeal metastasis: A propensity score matching analysis..